Elemind’s neuromodulation headband  shapes brain waves to help people fall asleep faster than leading sleep drugs and without side effects, using EEG monitoring and acoustic stimulation through bone conduction. Outperforms 5 of 6 prescription treatments in reducing sleep onset latency [Nature paper]. Developed out of an MIT lab led by co-founder Ed Boyden (Y. Eva Tan Professor in Neurotechnology at MIT and pioneer in optogenetics and expansion microscopy). Co-founded by inventor and entrepreneur Meredith Perry.

Acta is an Alzheimers drug development company undertaking two programs: (1) GSM-776890, which is the top prospect out of beta-amyloid-lowering drugs entering clinical trials (essentially a “statin for the brain”); and (2) ACT-I, which repurposes and screens combinations of known drugs to treat neurodegeneration, using mini-human brain orgonoids to test for synergies. Founder is Dr. Rudy Tanzi, PhD (one of TIME’s 100 Most Influential People of 2015; Director of the Genetics and Aging Research Unit at Harvard/MGH; Vice-Chair of the Neurology Dept). Dr. Tanzi co-discovered the genes responsible for early-onset familial Alzheimer's disease, including the amyloid precursor protein (APP) gene and the presenilin genes (PSEN1 and PSEN2), and contributed to the discovery of the Huntington's disease gene.

EightySix is a neurotech/AI company leveraging the brain’s neuroplasticity to gradually replace old brain tissue with new, synthetic lab-grown brain tissue derived from a patients induced pluripotent stem cells. The vision is to extend lifespans and treat most neurodegenerative diseases preventatively by enabling piece-by-piece replacement with an optimized clone brain. Furthermore, the approach could optimize high-throuput brain-computer interfacing with the integration of electrodes or nano particles into the process. Founder Daniel Burger hails from the Blue Brain Project.

Expansion Technologies is optimizing and applying revolutionary tools– including expansion microscopy (which permits nano precise imaging of large scale brain tissues), optogenetics, and high-speed brain activity imaging– to open up new frontiers in confronting brain disease and simulating the brain. Expansion is co-founded by Ed Boyden (Y. Eva Tan Professor in Neurotechnology at MIT and leading pioneer of both optigenetics and expansion microscopy).

NeuroAge Therapeutics is pioneering an AI-driven method to prevent and stop the progression of neurodegenerative disease by tackling root causes of brain aging, rather than focusing solely on the removal of toxic protein buildup.

Cognigenics is developing a long-acting therapeutic that uses short hairpin RNA-based therapeutics to mitigate the consequences of chronic stress and other disorders that arise from chronic neural dysregulation.

QBio, short for Quantified Biology, makes clinical digital twins and personalized health forecasts a reality. Their imaging tech will automate physical exams, generate risk summaries, and determine whether patients need to be triaged and routed to other specialists or take additional exams– all without the need of a doctor. Provides risk insights for health issues in otherwise asymptomatic populations and gives clinical follow-up recommendations– has already caught previously undiagnosed breast cancer in one of our associates.

BeSound is developing AI-driven photoacoustic imaging tech to detect cancer with ultrasounds. Their tech stack is made up of a hardware unit that integrates with existing ultrasound infrastructure and subscription-based software that uses generative AI to flag malignancies for doctors. Bloch has a research/development contract with Mass General Hospital (MGH) and Harvard Medical School.

Dognosis is developing a breath-based multi-cancer early detection (MCED) test by combining canine olfaction with AI-powered brain-computer interface (BCI) technology. Their DogSense BCI, a non-invasive headset that captures dogs' neural and behavioral responses to scent, essentially translates olfactory signals into digital data. These are analyzed by DogOS machine learning models to create disease signatures. In studies, they achieved 98% accuracy in detecting 10 cancers after 10 weeks of canine training. In practice, patients’ breath samples will be sent to Dognosis' lab, where trained dogs equipped with DogSense BCI analyze them for early disease detection.

Malcova creates medical technology that empowers accurate and efficient diagnosis of breast cancer and stroke through the use of proprietary deep-tech imaging and an AI-based diagnostic agent. They have raised $6M in government funding to date and are moving into clinical study with Yale University.

Mercy is developing a non-invasive, blood-based assay to make cancer screening globally accessible. Mercy’s Halo Ovarian Cancer Test received Breakthrough Device designation from the FDA for early detection of asymptomatic ovarian cancer in post-menopausal women after unblinding unprecedented results; Mercy substantially outperformed the traditional blood test in detecting ovarian cancer (CA125 liquid biopsy). Nobel Prize winner, Randy Schekman, the “godfather” of exosomes, is a highly engaged board member.

Feminai empowers women to do more accurate self-breast exams. Their tech includes a wearable, disposable patch paired with AI algorithms that identify abnormal lesions through blood flow and conductivity changes. They have successfully screened over 100 patients with 96% sensitivity and 98% NPV (Negative Predictive Value).

Imago Systems’ software detects breast cancer in women with dense breast tissue earlier than it is typically picked up, and shows promise in cardiovascular applications and other tissues as well, as a cloud-based Medical Software as a Service (MSaaS) solution. In partnership with Mayo Clinic, 475 cardiovascular facilities, the American College of Cardiology Company, MexAxiom, 20k cardiologists, KOLS, and more.

NorthStar Care is a virtual alcohol treatment program that differs from traditional rehab in its use of evidence-based medications and remote long-term counseling. So far, NorthStar has shown 91% patient retention and 94% success rate (compared to the 13% rate of inpatient rehab). Led by Amanda Wilson, a board-certified addiction medicine physician, who has been instrumental in developing two transformative Substance Use Disorder treatment programs, CleanSlate and Boulder Care, which together have treated over 25K patients.

Allia Health reimagines the tech stack for mental health care. Their vertically integrated platform uses a system of ML models to organize, analyze, and extract insights from biological, clinical, and behavioral data. Their flagship product is the first Gen-AI assistant for mental health clinicians– delivering instant, contextualised, research-based insights and automated, code-compliant documentation. By building a world-class data repository that captures treatment and outcome data, Allia is pioneering a learning mental health system, and has generated huge early excitement among providers– with >$300K in LOIs from over 14 clinics based off of early results.

Outro is building the first digital healthcare platform dedicated to safely tapering off of psychiatric medications, initially focusing on antidepressants. Cofounder is Dr. Mark Horowitz, expert on deprescribing and leader in the hyperbolic tapering method. He also authored the first deprescribing textbook and contributed to new UK National Guidelines on deprescribing.

Firefly VR is creating a VR meditation and mindfulness platform that blends tech and therapies to ease the symptoms of anxiety, depression, and other mental health issues. The VA is in various stages of planning or carrying out eight clinical trials alongside Firefly and has already made purchases. Comes from the minds of some of top video game veterans who have developed games including Guitar Hero and Wii Fishing.

ReMinded’s mission is to become the leading solution in salivary diagnostics. Their current focus is on pioneering a rapid, saliva-based biosensor focuses on enhancing detection of mental health conditions related to stress such as PTSD and addiction by analyzing cortisol levels. Their non-invasive device provides real-time, quantitative values in saliva within just minutes, enabling clinicians to make more accurate, data-driven decisions over time, minimizing the dependency on subjectivity. With plans to expand to a comprehensive set of hormones and biomarkers, ReMinded’s tech aims to offer broader applications for remote testing across various health conditions. Since officially forming their team in March 2024, ReMinded has raised close to $1M in total funding, with 2025 focused on clinical validation and FDA regulation. Won Google’s Pitching Competition in 2023 and invited to present at Stanford’s Innovators Forum of 2024.

Vertility Health is introducing an accessible and affordable technology for prospective parents looking to prevent mutations from being passed on through sperm sorting tech– which could allow parents to eliminate the costly step of screening embryos with preimplantation genetic testing (PGT) from the IVF process, and would allow some couples to bypass IVF altogether.

Genie is developing the first comprehensive test of womb health– which is a common and typically treatable cause of infertility issues, though underrecognized in comparison to the other major causes of infertility (sperm and embryo/egg health issues). Their menstrual blood test detects biomarkers relating to inflammation, hormones, heavy metals, chronic bacterial/fungal infections + more.

Amira Health is an AI precision health intervention company that supports women as they navigate menopause. Their approach is two-fold: they offer a smart cooling wearable device, ‘Terra,’ that detects hot flashes and provides instant relief during the night through an integrated mattress pad to reduce sleep interruptions; and an AI coach that removes guesswork from symptom management. 

Stealth reproductive company led by Y-Combinator founders and a Harvard pioneer in genetics and molecular engineering

Bexson Biomedical’s novel pain management system is entering the clinical stage to alleviate reliance on opioids. By using a pump to deliver drugs subcutaneously that have traditionally required other forms of delivery (like IVs), Bexson safely and effectively treats pain from home. Its lead target is focused on delivering low-dose ketamine subcutaneously for post-op pain management; it also holds an omnibus patent for new composition of matter patents on 100+ existing drugs across IV, oral, subQ and other delivery forms.

Empo Health is creating a digital ‘smart mat’ for early-stage detection and prevention of diabetic foot ulcers (DFUs)– which incur $40B in costs in the US each year. In its private practice usability study, Empo caught potential wounds or ulcers early in seven of 21 patients over three months. The Empo Team, led by founder Anuj Khandelwal, has already lined up LOIs with private practices for roughly 2,900 patients over initial sales and pilot periods. Coinvestors include Draper Associates, Boost.vc, and Cartograph.

Agate Health empowers medical professionals to focus on patient care through its digital health platform tailored to chronic conditions. Agate has received a $20K grant from the National Science Foundation & Public Policy Lab. Led by Naciim Mohamed, a Gates Scholar and prior founder.

RTHM is a YC-incubated company integrating remote clinical medicine and research with advanced molecular/digital measurement tech + AI, in order to bring diagnostics and treatments to patients faster. Initial focus is on Long Covid. Founders include Ryan Kellogg, PhD, a pioneer of tech for molecular profiling using self-collected blood microsamples at Stanford; and Jennifer Curtin, MD, a physician and post-viral illness expert specializing in ME/CFS, and a co-author on the official clinical guidance for ME/CFS

ModoScript is a remote treatment monitoring AI solution that guides clinical trial participants and patients as they take oral specialty therapeutics– preventing accidental overdoses, underdosing, and diversion. Their device collects vitals as medication is dispensed, and displays AI-enabled visual and vocal treatment interaction content on a screen. The company is poised to capitalize on the shift to at-home clinical trials.

Starling Medical is a YC-incubated company that detects biomarkers for chronic health diseases with at-home urine tests and gives AI-generated diagnoses and risk assessments. It tests markers for UTIs, prostate health, kidney disease, kidney stones, heart failure, and diabetes/CKD.

Parallel Health is an AI-driven skincare company maiking products tailored to customers’ skin microbiome types. They have developed customized skincare products that can reduce acne, inflammation, skin lesions, and signs of aging, based on the patients’ distinct skin microbiome type. Their customized serums are made out of a specific selection of phages (small microbes that deactivate specific bacteria).

Above Health offers an AI/ precision health clinic for food allergies, focused primarily on treatment programs, community support, and diagnostic and testing services, and eventually nutrition services. Team includes Dr. Nana Mireku, who operates a top allergy clinic in Texas; Dr. Matthew Truebe, who has had multiple exits and over $600M raised for prior companies; and Dr. Saba Haq, an emergency medicine physician, medical director, and startup advisor.

Enov.one provides personalized AI concierge medicine at scale, incorporating data from lab tests, genetics tests, and wearables to address root causes of chronic health issues. Recently launched JoyfulRx, a precision health program for pre- and post-menopausal symptom relief, and also is uniquely suited to treat depression, anxiety, brain fog, fatigue, and other unexplained mental health problems through SNP analysis. Coinvestors include Draper Startup House, Boost.vc and Cartograph.

SeeMedX is developing a stroke volume and fluid management technology that gives warning of acute heart failure 48 to 72 hours in advance, with a proprietary and non-invasive device. Received two FDA 510(k) approvals and led by NASA-veteran team that includes Deborah Simpson, CEO; Dr. Kevin Ferguson, Chief Product Officer; and Dr. Marc O Griofa, Chief Medical Officer.

Jona uses LLMs to reveal the relationship between the microbiome and personal health. Following testing, Jona's unique AI system reads all of the scientific studies and matches the microbiome results to every disease, symptom and allergy that has been identified in the literature. Then, Jona's AI analyzes the effect of actions on your microbiome by determining the effect of every known dietary, lifestyle, supplement and medication choice on all matched diseases, symptoms and allergies– by creating, for every possible intervention, a virtual microbiome (i.e., microbiome digital twin) and determining whether the virtual microbiome with that action improves your microbiome's matching to disease.

Alden Scientific is applying an ML approach to the world's most comprehensive biological data to create individual predictive models of human health and disease– including covering most of the leading causes of mortality and morbidity like heart disease, stroke, diabetes, and Alzheimer’s. Their models fuse diverse datasets including proteomics, genetics, epigenetics, and antibody profiling, enabling them to stratify an individual's current health and risk of 200+ conditions with a performance of up to 40x better than current biomarkers. Team has experience in drug development and disease discovery at top institutions including ALS-TDI, PatientsLikeMe, The Broad Institute, Dana-Farber, AOBiome, Genetic Networks, and iCarbonX; Led by co-founders JamieHeywood and JeffCole.

I2Pure is an iodine technology company dedicated to advancing health and biosafety through its patented, non-toxic molecular iodine solutions. Their mission is to prevent pathogenic threats to the world. The platform tech can be delivered directly or through carriers via solutions, nano particles, polymers and coatings; and has many applications– across healthcare, industrial biosafety, consumer products, and food processing

ImYoo partners with patients to collect rich molecular data across disease and treatment, powering precision medicine

Glyphic Biotechnologies is pioneering proteomics– developing the only sequencing platform in the world to enable researchers to discover novel proteins and protein targets in a truly scaleable and cheap way. It has demonstrated proof of feasibility for their protein sequencing; filed 32 patent/patent applications globally; and built a backlog of customers that includes the NIH ($1.1M), NY Biodefense Fund ($2.8M), and an unnamed US agency ($1.5M).

Motley Bio is building a novel multianalyte sequencing technology to simultaneously profile DNA, RNA, and proteins in a single sequencing readout. This enables simultaneous measurement of a sample’s genome, epigenome, transcriptome, and proteome for disease detection and profiling. Their core IP will extend to both comprehensive tissue and liquid biopsy profiling to support the next generation of diagnostics and therapies. Applications extend beyond medicine.

Cellular Vehicles is unlocking a multi-billion-dollar cell and gene therapy (CGT) market by enabling a ten-fold increase in the number of hospitals that can deliver these incredible treatments to their patients. They are using robotics, microfluidics, and machine vision to build something akin to a “CGT Nespresso Machine” to consolidate the required clinical infrastructure into a box and in turn allow any hospital to offer these treatments without the need for a specialty pharmacy.

Co-investors include BoostVC and Sand Hill Angels.

NAVAN is innovating a non-viral delivery platform with a nanotech approach towards the genetic engineering of human primary cells, capable of delivering DNA, mRNA, and proteins, including Cas9 and other functionally-active proteins, with high efficacy. Winner of Bristol-Myers Squibb MBC Golden Ticket 2022 and in partnership with MD Anderson for validation.

Sentinal4D is an AI-driven cancer drug discovery company that leverages 3D cell shape biology and clinical data to accelerate the cancer drug development process and predict patient-specific responses to therapies. Led by Dr. Chris Bakal, a globally recognized pioneer in cell systems biology.

Mitrix Bio is pursuing a longevity breakthrough by replenishing the body's natural battery with bioreactor-grown mitochondria. Mitrix's tech wraps lab-grown mitochondria in a proprietary coating and receptors to target specific tissues, and then transplants the mitochondria into tissues, organs and cells via naturally-occurring metabolic pathways. Approaching Phase I trials. At Stanford, UConn, and Quebec, Mitrix tested in small animals, showing that mitochondria crossed the blood-brain-barrier, reversed immune system function age significantly, and regenerated mitochondrial function in a mouse brain.

Vivan Therapeutics is developing novel cancer drug combinations by leveraging AI/ML and personalized disease models. It replicates a patient’s genetic profile and tumor network and screens thousands of drug cocktails against it.

Superbio offers the first AI marketplace for biotech to democratize AI for drug discovery and development. Its platform offers affordable AI-based tools and models that result in savings through faster/more accurate predictions of drug candidates. It improves analytics across the research value chain– serving university labs, research institutions, and pharma companies. Currently in collaboration with Google and the Center for Reproducible Biomedical Modeling

MoveJoy, founded by Equinox Co-founder Lavinia Errico, is an AI wellness company that offers holistic on-demand classes that empower women to achieve physical, mental, and emotional well-being through various fitness courses and women’s health workshops.

Othership promotes wellness through its studios that offer saunas, ice baths, and guided breathwork sessions, serving as a non-alcoholic space to socialize and form community. In <1 year, its first location (Toronto) generated a 5.0 rating with >350 Google reviews; mentions in Forbes, Vogue and 75 podcasts.

Novobeing is redefining patient care with immersive technology that transforms the healthcare experience. Their clinically validated virtual and mixed reality (VR/MR) platform delivers evidence-based programs that reduce stress, anxiety, and pain—helping providers elevate patient satisfaction and well-being. Designed for seamless integration and effortless use, Novobeing makes high-quality therapeutic care accessible anywhere it's needed.

Endo Health makes weight loss simple: Just answer your phone. Their AI-powered voice companion provides personalized, proactive health coaching through phone calls and text messaging, building genuine rapport and accessibility for middle-aged adults. Founded by medical doctors, MIT PhDs, and former engineering leaders at Krafton. Backed by top-tier investors including a16z speedrun, General Catalyst, and Anne Wojcicki (Co-founder & CEO, 23andMe).

Superhumn is an alt-protein food tech company seeking to expand mass consumer access to healthy, sustainable foods. It has industry-high margins and 90% lower R&D and manufacturing costs than competitors, with impressive early traction, including a launch on Walmart Marketplace and $2.2M of contracts.

OnFirm– HealthyHospitals is creating a software-based system to deliver healthy, restaurant-quality food to hospitals in a scaleable, cost-effective way. Founder Jeffrey Jacobs has experience doing this with 24+ different hospitals– including Northwell Health, the largest health system in New York. Patients’ Press-Gainey satisfaction scores increased from 9% to 90% during his implementation period at Northwell, while food costs rose only 2%.

Concha Labs addresses hearing loss with a patented AI software platform that personalizes hearing aids to a higher degree than traditional audiology. The team has already signed agreements with Best Buy and is in advanced discussions with Costco, which handles 15% of U.S. hearing aid sales. Additionally, Mayo Clinic is now recommending Concha as their preferred OTC hearing aid. Altogether, Concha’s team has decades of experience in the hearing aid industry, and they’re led by founder Amy Li, who has had hearing loss since kindergarten.

MetaFlex is a patented innovation that combines gentle compression with adjustable resistance bands for passive pain management, grip strengthening, and finger stretching designed to improve hand function. MetaFlex gloves are a comprehensive hand health solution - sold on Amazon, Walmart.com, MetaFlexGlove.com, the VA Medical Centers, and dozens of pharmacies across the U.S.

Feno is creating an AI/ML-powered oral care device that includes a toothbrushing mouthpiece and a scanner.  In 20 seconds, the mouthpiece component removes plaque better than manual and electric brushes and detects oral health issues like enamel erosion, gingivitis, or other signs of disease. Feno is partnered with Nvidia for AI models of oral health and imaging analysis, UC San Diego for salivary biosensor development, and University of Minnesota for an RCT.

Lynx Tech is positioned as the most private and personalized AI assistant yet. It harnesses users’ personal data to serve as an AI digital assistant– keeping users up to date on their lives, answering their questions, and filtering out the noise from their messages and alerts. It creates a secure local model that only the user has access to, harnessing data for customers without it ever leaving their device, providing safe applications in personal health.

NextThought AI helps post docs secure funding by automating large sections of grants with AI trained on technical and complex proposals and by streamlining the application process. The AI beta product was already revenue-generating a month after its launch, with ~150 active users and 100+ applications.

The Natural Nipple created an infant bottle with innovative biomimicry-inspired design enabled by AI. Because the bottle’s tip is personalized to a mother’s unique shape, feel, and flow, it makes for better bottle feedings and is far less disruptive to breastfeeding than the typical bottle– minimizing latching time, frustration, colic, and other feeding-related challenges.